CoChat
Sign Up
Cited by 401Lipid metabolism and biosynthesisAdipose Tissue and MetabolismLipid metabolism and disorders

The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.

Human fat cell lipolysis: biochemistry, regulation and clinical role.

Arner, Peter·2005·Best Practice & Research Clinical Endocrinology & Metabolism
DOI 10.1016/j.beem.2005.07.004
Open this paper in CoChat — free account

Abstract

Release of fatty acids (FAs) from adipose tissue through lipolysis in fat cells is a key event in many processes. FAs are not only energy substrates but also signalling molecules and substrates for lipoprotein production by the liver. Fat cells consist of>95% triglycerides that are hydrolysed during lipolysis to glycerol and FAs. The major rate-limiting factor for lipolysis is hormone-sensitive lipase, but additional lipases such as adipose tissue triglyceride lipase may also play a role. The regulation of human fat cell lipolysis is, in many ways, species unique. Only catecholamines, insulin and natriuretic peptides have pronounced acute effects. Catecholamines influence lipolysis through four different adrenoceptor subtypes, in contrast to rodents where only one subtype (beta(3)) is of major importance. There are regional variations in adipocyte lipolysis leading to more release of FAs from the visceral than subcutaneous adipose tissue during hormone stimulation (insulin, catecholamines). Since, only visceral fat is linked to the liver (by the portal vein), alterations in visceral adipocyte tissue lipolysis have direct effects on the liver through portal FA release. The regional variations in lipolysis are further enhanced in obesity and polycystic ovarian syndrome, and are of importance for dyslipidaemia, hyperinsulinaemia and glucose intolerance in these conditions. There is a marked elevation of circulating FA levels among the obese, which may be due to enhanced production of tumour necrosis factor alpha in adipose tissue. This cytokine stimulates lipolysis through so-called MAP kinases. Pharmacological agents in clinical practice such as nicotinic acid and glitazones exert lipid-lowering and glucose-lowering effects, respectively, by decreasing FA output from the adipose tissue. This review covers the biochemistry, regulation and clinical aspects of human fat cell lipolysis.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.beem.2005.07.004

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 46 references

2 of the 46 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Items 301–400 of 401

Related

See all

Metadata

Authors
Arner, P.
Affiliations
Karolinska University Hospital (SE)
Corresponding author
Arner, Peter
ORCID
Arner, Peter
Venue
Best Practice & Research Clinical Endocrinology & Metabolism
Publisher
Elsevier BV
Published
2005-12
Volume
19
Issue
4
Pages
471-482
ISSN
1521-690X (ISSN-L)
DOI
10.1016/j.beem.2005.07.004
OpenAlex
W1981933686
Cited by
401
References
46
Citations by year
2026: 15 · 2025: 8 · 2024: 12 · 2023: 9 · 2022: 19 · 2021: 20 · 2020: 19 · 2019: 17 · 2018: 10 · 2017: 18 · 2016: 14 · 2015: 14 · 2014: 27 · 2013: 30 · 2012: 25
FWCI
2.63
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Best Practice & Research Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
adipocyte lipolysis, fatty acid release, hormone-sensitive lipase, catecholamines, adrenergic receptors, insulin, natriuretic peptides, visceral adipose tissue, subcutaneous adipose tissue, portal vein, hepatic lipoprotein production, obesity, polycystic ovary syndrome, TNF-α, mitogen-activated protein kinase, nicotinic acid, thiazolidinediones, dyslipidemia, hyperinsulinemia, impaired glucose tolerance
MeSH terms
Catecholamines, Female, Humans, Insulin, Lipolysis, Obesity, Polycystic Ovary Syndrome, Triglycerides, Adipocytes, Natriuretic Peptides, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review